# Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?

> **NCT04813939** · — · TERMINATED · sponsor: **Medical University of Warsaw** · enrollment: 32 (actual)

## Conditions studied

- Covid19

## Interventions

- **DEVICE:** IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany)

## Key facts

- **NCT ID:** NCT04813939
- **Lead sponsor:** Medical University of Warsaw
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-22
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Enrollment was terminated because of the poor recruitment rate.
- **Last updated:** 2022-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04813939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04813939, "Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT04813939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*